Document is current
Any future updates will be listed below
-
Authors
Delgado-Velandia, Mario
Gonzalez-Marrachelli, Vannina
Domingo-Relloso, Arce
Galvez-Fernandez, Marta
Grau-Perez, Maria
Olmedo, Pablo
Galan, Iñaki
Rodriguez-Artalejo, Fernando
Amigo, Nuria
Briongos-Figuero, Laisa
Redon, Josep
Martin-Escudero, Juan Carlos
Monleon-Salvado, Daniel
Tellez-Plaza, Maria https://orcid.org/0000-0002-3850-1228
Sotos-Prieto, Mercedes
-
Funding
Funding for this research was provided by:
European Commission (EPSS-037093)
Instituto de Salud Carlos III (PI10/0082, PI13/01848, PI14/00874, PI16/01402, PI11/00726, PI16/609, PI16/1512, PI18/287, PI19/319 and PI20/00896, CIBER-02-08-2009, CB06/03 and CB12/03/30016, FI20/00162, CD16/00255)
GUTMOM Project (INTIMIC-085; of R+D+I PCIN-2017-117)
Cátedra de Epidemiología at UAM (820024)
Agencia Estatal de Investigación (PID2019-108973RB-C21 and C22)
Valencia Government (GRUPOS 03/101; PROMETEO/2009/029 and ACOMP/2013/039)
Castilla-Leon Government (GRS/279/A/08)
Ministerio de Ciencia, Innovación y Universidades (RYC-2018-025069-I)
“la Caixa” Foundation (LCF/BQ/IN18/11660001, LCF/BQ/DR19/11740016)
- License Information
-
More Information
Article History
Received: 12 March 2021
Accepted: 20 October 2021
First Online: 27 January 2022
Declarations
:
: The research protocol and each phase of the study were approved by the Ethics Committee of the University Hospital Rio Hortega (committee’s reference number, CEIC/12/01/03). All participants provided written informed consent.
: Not applicable.
: N.A. is stock owner of Biosfer Teslab, the company that commercialize the lipoprotein profiling described in the present manuscript, and has a patent for lipoprotein profiling. All other authors declare that they have no competing interests.
